瘤学剂量优化:针对不同分子类的量身定制方法.
Jiawen Zhu1, Amy Schroeder1, Sabine Frank2
1Genentech, South San Francisco, California, USA.
Clinical pharmacology and therapeutics
|April 18, 2025
概括
优化瘤药物剂量正在从最大耐受剂量 (MTD) 转向针对性疗法和免疫疗法的量身定制方法. 一个新的框架对药物进行了分类,以提高疗效和降低毒性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药物开发 药物开发
背景情况:
- 传统的化疗剂量优化侧重于最大耐受剂量 (MTD),往往导致显著的毒性.
- 新兴的向疗法和免疫疗法允许在较低剂量,低于MTD时具有效果,并减少副作用.
- 最近的FDA指导强调在瘤药物开发中改进剂量优化策略.
研究的目的:
- 为瘤药物开发中量身定制的剂量优化提供一个新的框架.
- 根据作用机制和临床活性将瘤分子分为四个不同的类别.
- 讨论每个分子类别的独特剂量优化考虑因素.
主要方法:
- 瘤分子分为四个类别:第1类 (小分子向疗法,抗体-药物合物),第2类 (大分子抗剂),第3类 (癌症免疫疗法激动剂) 和第4类 (具有有限单剂活性的分子).
- 讨论每个类别的特定剂量优化策略,并以案例为支持.
- 建议使用活性证明作为启动剂量扩张的标准.
主要成果:
- 一个拟议的框架用于分类瘤药物,以指导剂量优化.
- 确定四个分子类别中的每一个单独的剂量优化考虑因素.
- 强调整合临床前数据,疾病知识和临床测量,以确保可靠的决策.
结论:
- 一种新的基于类型的瘤剂量优化方法可以提高疗效并最大限度地降低毒性.
- 使用活性证明作为剂量扩张的门,可以改善决策和资源分配.
- 定量药理和统计建模对于优化瘤药物剂量至关重要.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer
48.2K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
48.2K
Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334


